- Regeneron reaches $125M Parabilis deal for hard-to-catch drug targetsAs Regeneron’s cancer portfolio continues to suffer setbacks, the company is placing a bet in a different direction through a deal with Parabilis Medicines valued at as much as $2.2 billion. Para…Endpoints · 2mo ago↗ source
- Design Therapeutics' Friedreich's ataxia data; Vincentage's obesity results from ChinaPlus, news about Enhertu and Tecentriq. 💪 Design Therapeutics shares Phase 1/2 data in Friedreich's ataxia: The California biotech’s DT-216P2 given at 1 mg/kg led to an average 6.4-point improve…Endpoints · 2mo ago↗ source
- Merck's ADC sac-TMT gets its first global Phase 3 win ahead of scheduleAn experimental antibody-drug conjugate from Merck and China-based Kelun-Biotech succeeded in a global Phase 3 study for the first time, giving Merck a key pipeline victory as it approaches the pat…